SBC Medical Q3 Revenue Jumps 35% as Operating Income Climbs 66%
SBC has more than doubled off its 52-week low of $2.78.
Summary
SBC Medical posted a sharp reacceleration in Q3 2026: revenue of $59 million, up 35% year-over-year, and operating income of $26 million, up 66%, for a 45% operating margin. Adjusted EBITDA rose 66% to $28 million with the margin expanding 9 points to 47%. Net income attributable to the company was $16 million, up 22%, but the net margin slipped 3 points to 27% as taxes and minority interest took a bigger bite. Growth came from higher management services revenue, including August's service fee revisions, plus consolidation of Waqoo; the clinic network reached 293 locations, up 36 year-over-year, with 7.06 million trailing-twelve-month patient visits, up 9%. The balance sheet is the quiet story: $198 million in cash and $154 million in net cash after $50 million of nine-month operating cash flow, against a roughly $549 million market cap. That cash pile funds the AI/LLM buildout, the Atomic Software alliance, the Longevity diagnostics push and US/ASEAN expansion. The company holds its earnings call today at 8:30 a.m. ET.
At the time of this announcement, SBC was trading at $5.71 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $549.2M. The 52-week trading range was $2.78 to $5.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.